|
WO2020231750A1
|
|
Method for alphavirus inhibition
|
|
WO2020205932A1
|
|
Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
|
|
TW202038970A
|
|
Combination compositions comprising a beta-lactamase inhibitor and uses thereof
|
|
WO2020056048A1
|
|
Combination compositions comprising a beta-lactamase inhibitor
|
|
EP3807246A1
|
|
Hepatitis b capsid assembly modulators
|
|
WO2019232053A1
|
|
Broad-spectrum carbapenems
|
|
EP3802551A1
|
|
Penicillin-binding protein inhibitors
|
|
WO2019118358A1
|
|
Hepatitis b capsid assembly modulators
|
|
CN110959008A
|
|
Penicillin binding protein inhibitors
|
|
WO2018218154A1
|
|
Penicillin-binding protein inhibitors
|
|
KR20190117790A
|
|
Solid forms and combination compositions comprising beta-lactamase inhibitors and uses thereof
|
|
EP3494121A1
|
|
Boron-containing compounds
|
|
WO2017100537A1
|
|
Beta-lactamase inhibitors
|
|
WO2017044828A1
|
|
Beta-lactamase inhibitors
|
|
US2015361106A1
|
|
Beta-lactamase inhibitors
|
|
US2015361108A1
|
|
Orally bioavailable beta-lactamase inhibitors
|
|
US2015361107A1
|
|
Orally bioavailable beta-lactamase inhibitors
|
|
CN106687465A
|
|
Beta-lactamase inhibitors
|
|
EP2970340A1
|
|
Beta-lactamase inhibitors
|
|
US2016016978A1
|
|
Beta-lactamase inhibitors
|
